StockNews.AI
PLRX
StockNews.AI
168 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX

1. Pliant Therapeutics is under investigation for potential securities fraud. 2. Enrollment in BEACON-IPF trial halted after DSMB recommendations. 3. Stock price fell 60.59% post-trial pause announcement. 4. BEACON-IPF trial discontinued due to adverse event imbalance. 5. Recent investigations could indicate wider issues in corporate governance.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The discontinuation of pivotal trials and ongoing legal investigations often lead to significant price declines, exemplifying Pliant's dramatic stock drop following adverse trial news.

How important is it?

The implications of legal investigations and trial issues can result in substantial financial impacts, making this highly relevant for PLRX investors.

Why Short Term?

Immediate impacts from the investigation and trial discontinuation are likely to affect investor sentiment and stock price promptly.

Related Companies

VRTXMRNAGNFT
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Pliant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On February 7, 2025, Pliant issued a press release "announc[ing] that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF)." Following this news, Wells Fargo and Citi analysts both downgraded Pliant, citing uncertainty about bexotegrast's path forward.  On this news, Pliant's stock price fell $4.72 per share, or 60.59%, to close at $3.07 per share on February 10, 2025.  Then, on March 3, 2025, Pliant issued a press release "announc[ing] that following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, Pliant has discontinued the BEACON-IPF Phase 2b trial evaluating bexotegrast in patients with idiopathic pulmonary fibrosis (IPF)." Pliant attributed the discontinuation to "an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups".  On this news, Pliant's stock price fell $2.06 per share, or 59.88%, to close at $1.38 per share on March 3, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLP[email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News